N-Methylated Linkers for PSMA Ligand Renal Clearance
Solution Overview
Problem
Current PSMA ligands used for imaging and treatment of prostate cancer exhibit high renal and salivary gland uptake, leading to significant side effects such as xerostomia, which limits therapeutic efficacy and patient safety.
Innovation Solution
Development of PSMA binding ligands with a specific linker structure comprising N-alkylated amino acids, particularly N-methylated amino acids, to enhance renal excretion and reduce non-target tissue uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PSMA ligands are used for imaging and treatment, then therapeutic efficacy is achieved, but renal and salivary gland uptake increases causing significant side effects
Solution Approach 1:
The patent applies local quality by modifying the chemical structure of PSMA ligands at specific positions (introducing N-alkylated amino acids at defined locations in the linker sequence) to create regional differences in binding characteristics. This localized structural modification enables selective enhancement of renal clearance while preserving PSMA binding affinity, thereby reducing salivary and lacrimal gland uptake without compromising therapeutic efficacy.
Solution Approach 2:
The patent implements parameter changes by systematically varying chemical parameters of the PSMA ligand structure, specifically introducing N-alkylated amino acids with different alkyl chain lengths and positions in the linker sequence. These parameter modifications alter the pharmacokinetic properties of the ligand, optimizing renal excretion while maintaining target tissue binding, thus reducing harmful side effects.
2Measurement precision
If PSMA ligands with high affinity are used to improve tumor targeting, then imaging quality improves, but non-target tissue uptake increases
Solution Approach 1:
The patent applies segmentation by dividing the PSMA ligand into distinct functional segments: a PSMA binding motif (Q), a linker region containing N-alkylated amino acids (X1), and a chelator residue (A). This segmentation allows independent optimization of each component - the binding motif maintains high affinity for tumor targeting, while the modified linker segment enhances renal clearance, and the chelator ensures stable radionuclide attachment, thereby improving imaging quality while reducing non-target tissue uptake.
Solution Approach 2:
The patent uses the linker region containing N-alkylated amino acids as an intermediary element between the PSMA binding motif and the chelator. This intermediary structure mediates the pharmacokinetic behavior of the ligand, facilitating rapid renal excretion while allowing the binding motif to maintain high affinity for PSMA on tumor cells, thus improving imaging quality without increasing non-target tissue accumulation.
3Reliability
If conventional PSMA ligands are administered, then treatment is effective, but salivary and lacrimal gland uptake causes xerostomia
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of PSMA ligands, specifically introducing N-alkylated amino acids at defined positions in the linker sequence. These structural parameter modifications alter the ligand's interaction with renal transporters, enhancing clearance through the kidneys while preserving PSMA binding affinity, thereby maintaining treatment effectiveness while reducing salivary and lacrimal gland uptake that causes xerostomia.
Solution Approach 2:
The patent converts the potentially harmful high renal uptake of conventional PSMA ligands into a beneficial feature by strategically placing N-alkylated amino acids in the linker. This modification redirects the ligand's affinity toward renal excretion pathways, transforming what was previously a source of toxicity (renal and salivary gland accumulation) into a beneficial clearance mechanism that reduces side effects while maintaining therapeutic efficacy.
Data Source
AI summary
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof. In particular, the present invention relates to a PSMA binding ligand or a pharmaceutically acceptable salt or solvate thereof comprising a PSMA binding motif Q and a chelator residue A linked via at least one linker LAQ, the linker comprising at least one N-alkylated, preferably N-methylated amino acid.